查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1912616

按製剂形式、技术、治疗适应症、最终用户和通路分類的组合外用药物市场—2026-2032年全球预测

Compounded Topical Drug Market by Formulation, Technology, Therapeutic Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，复方外用药物市场价值将达到 51.2 亿美元，到 2026 年将成长至 54.1 亿美元，到 2032 年将达到 84.2 亿美元，年复合成长率为 7.36%。

关键市场统计数据
基准年 2025 51.2亿美元
预计年份：2026年 54.1亿美元
预测年份 2032 84.2亿美元
复合年增长率 (%) 7.36%

权威概述了组合外用疗法，阐述了临床需求驱动因素、製剂柔软性以及不断发展的给药生态系统。

复方外用製剂处于个人化医疗和实用局部给药的策略性交会点。在临床医师对个人化给药和製剂柔软性的需求驱动下，复方外用治疗方法需求，弥补了现有标准药物的不足。在临床实践中，这些製剂用于优化治疗指数、控制辅料不耐受，并在证据和临床判断表明有益时支持仿单标示外通讯协定。

监管力度加大、配方创新和数数位化医疗服务将如何融合，重塑复方外用药物的实践和商业化？

复合外用治疗药物领域正经历变革性的转变，这主要由监管、技术和医疗服务三方面因素的融合所驱动。监管机构正在完善指导方针，以加强品管，同时保持个人化配製流程，这促使配製机构投资于标准化流程、完善文件记录和批次级可追溯性，以满足日益增长的安全性和透明度要求。

检验2025年关税趋势对药局相关人员采购多元化、近岸外包措施和供应链韧性策略的影响

美国2025年实施的关税政策变化，为依赖进口原材料、包装和特殊剂量组件的製造商和配药机构的供应链规划带来了更多复杂性。某些辅料和聚合物基质关税的提高，迫使采购部门重新评估其采购区域，并考虑具有同等品质认证的替代供应商。这些调整通常需要检验配方并进行稳定性测试，以确保在引入替代材料时保持治疗等效性。

详细的細項分析揭示了製剂类型、治疗用途、通路、最终用户和贴剂技术如何决定临床应用和营运优先顺序。

细分市场洞察揭示了不同製剂类型、治疗适应症、分销管道、终端用户环境和底层技术所决定的独特策略要务。按製剂类型分類的市场分析涵盖乳膏、泡沫剂、凝胶剂、洗剂、软膏剂和喷雾剂。每种製剂的应用特性和稳定性各不相同，这会影响处方行为和患者依从性。当润肤效果是首要考虑因素时，乳膏和洗剂是首选；而凝胶剂和泡沫剂则适用于需要美观且快速干燥的应用。当需要封闭或特定接触模式时，喷雾剂和软膏剂则发挥独特的作用。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和监管差异将影响市场准入途径和商业化策略。

区域趋势正在影响全球主要市场中复方外用药物的取得、监管预期和商业化路径。美洲地区拥有成熟的临床应用环境，其特点是医院药房基础设施完善，且高度主导。监管机构强调复方製剂的品质标准和不利事件报告，而私人医疗系统通常会整合专科药房服务，以支持复杂的个人化治疗方案。

在局部用药配送领域，以品质为导向的药局供应商与以交易为导向的供应商之间的关键竞争优势和伙伴关係模式是什么？

在复方外用药物领域，竞争优势主要体现在三大核心支柱：可验证的品质系统、以临床为导向的服务模式以及可扩展的生产和供给能力。领先的复方製剂企业将投资于检验的设施、完善的无菌和稳定性测试通讯协定、机构合约以及透明的文件记录，从而增强临床医生的信心。这些投资不仅能降低风险，还能在竞标评估和处方集选择过程中脱颖而出。

为产业领导者提供可操作的策略重点，以协调供应链韧性、临床证据产生和全通路分销，从而保持竞争优势。

为确保永续优势，产业领导者应优先考虑一项三管齐下的行动计划，该计划需兼顾供应链韧性、临床证据产生和管道整合。首先，应透过原材料来源多元化、尽可能投资近岸外包以及实施包含变更管理和稳定性桥接研究等文件的先进供应商选择框架来强化供应链结构。这些措施将降低关税和物流波动带来的风险，并保障患者持续获得所需药物。

我们严谨且以实践者观点的调查方法，整合了深度访谈、监管审查和技术文献，旨在提供可操作的洞见。

本分析的调查方法结合了结构化的原始研究、监管审查和二手文献综述，以确保其全面性和实践观点。一级资讯来源包括对医院药房主任、配药药剂师、药房委员会成员和临床专家的深入访谈，以了解实践操作和临床决策驱动因素。这些访谈最终得出关于配药流程、品质预期和实施障碍的定性评估结果。

整合策略要务和实用建议，以协调局部用药配发中的临床个体化、营运弹性和监管要求

复方外用製剂是一种可行的个人化局部治疗手段，是对传统药物传递方式的补充。随着相关人员采纳高品质标准、投资製剂创新并重组供应链以应对地缘政治因素和关税带来的衝击，该领域正日趋成熟。临床医生仍然重视复方製剂的柔软性，以满足患者特定的剂量和製剂需求，而采购和监管相关人员相关者正在製定必要的规范，以确保安全可靠的用药途径。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以剂型分類的复方外用药物市场

  • 奶油
  • 形式
  • 凝胶
  • 洗剂
  • 软膏
  • 喷

9. 按技术分類的局部用药市场

  • 传统配方
  • 经皮贴剂
    • 矩阵补丁
    • 水库补丁

第十章：依治疗适应症分類的复方外用药物市场

  • 镇痛/疼痛管理
  • 抗发炎药
  • 抗菌剂
  • 抗真菌剂
  • 皮肤病
  • 创伤治疗

第十一章 依最终用户分類的组合外用药物市场

  • 诊所
    • 一般诊所
    • 专科诊所
  • 皮肤科诊所
  • 居家医疗环境
  • 医院

第十二章 按分销管道分類的外用药品市场

  • 医院药房
  • 网路药房
  • 零售药房

第十三章：各地区组合外用药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 组合外用药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国复方外用药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国组合外用药物市场

第十七章：中国复方外用药市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 3M Company
  • Ascend Laboratories, Inc.
  • Bausch Health Companies Inc.
  • Fagron NV
  • Fresenius Kabi AG
  • Idelle Labs Ltd.
  • ImprimisRx, LLC
  • Merck & Co., Inc.
  • PharMEDium Services, LLC
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-AE420CB13A63

The Compounded Topical Drug Market was valued at USD 5.12 billion in 2025 and is projected to grow to USD 5.41 billion in 2026, with a CAGR of 7.36%, reaching USD 8.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.12 billion
Estimated Year [2026] USD 5.41 billion
Forecast Year [2032] USD 8.42 billion
CAGR (%) 7.36%

An authoritative overview of compounded topical therapeutics framing clinical demand drivers, formulation flexibility, and the evolving delivery ecosystem

Compounded topical therapeutics occupy a strategic intersection between personalized medicine and practical, localized drug delivery. Driven by clinician demand for tailored dosing and formulation flexibility, compounded topical products enable treatment regimens that address heterogenous patient needs where commercial products may be inadequate. In clinical settings, these preparations are deployed to optimize therapeutic index, manage intolerances to excipients, and support off-label protocols when evidence and clinical judgment indicate benefit.

The broader ecosystem supporting compounded topical drugs includes compounding pharmacies, specialty pharmacists within hospital systems, and an evolving regulatory environment that aims to balance patient safety with access. Technological advancements in formulation science-ranging from novel excipients to controlled-release patch matrices-are enhancing both stability and transdermal penetration profiles. Meanwhile, digital health integration and telemedicine are extending the reach of prescribers and dispensing channels, prompting changes in how clinicians select and monitor topical regimens.

As stakeholders assess product strategy and clinical adoption pathways, understanding the interplay of formulation options, therapeutic indications, distribution channels, and end-user environments becomes essential. This introduction sets the stage for a deeper exploration of the structural shifts, tariff impacts, segmentation nuances, regional dynamics, and actionable recommendations that follow in the report.

How regulatory tightening, formulation innovation, and digitalized care delivery are converging to reshape the practice and commercialization of compounded topical therapeutics

The landscape for compounded topical therapeutics is undergoing transformative shifts driven by converging forces in regulation, technology, and care delivery. Regulators are refining guidance to strengthen quality controls while maintaining pathways for individualized preparations, prompting compounding facilities to invest in standardized processes, enhanced documentation, and batch-level traceability to meet heightened expectations for safety and transparency.

Simultaneously, formulation science is moving from conventional suspensions and creams toward platforms that enable controlled release and improved bioavailability. Advances in transdermal technology and excipient science are creating opportunities to substitute systemic therapy with localized delivery, reducing systemic adverse effects and improving patient adherence. Telehealth and digital prescribing are altering traditional distribution patterns: prescribers can initiate customized regimens remotely, and patients increasingly expect integrated follow-up and digital adherence support.

Commercial dynamics are shifting as well, with contract manufacturers and specialty pharmacies forming partnerships to scale validated compounding operations and provide clinical support services. Procurement teams within hospitals are prioritizing supplier qualification frameworks that emphasize sterility assurance, stability data, and supply continuity. These combined trends are catalyzing new business models where clinical outcome evidence, operational excellence, and regulatory compliance define market leadership.

Assessing how 2025 tariff evolutions are driving sourcing diversification, nearshoring initiatives, and supply chain resilience strategies for compounding stakeholders

Tariff policy changes in the United States during 2025 have layered additional complexity onto supply chain planning for manufacturers and compounding facilities that depend on imported raw materials, packaging, and specialized delivery components. Increased duties on certain excipients and polymer substrates have prompted procurement teams to reassess sourcing geographies and to evaluate alternative suppliers with comparable quality certifications. These adjustments often require revalidation of formulations and stability testing to ensure therapeutic equivalence when substitute materials are introduced.

In response to tariff-induced cost pressure, some organizations have accelerated nearshoring strategies and diversified supplier portfolios to reduce exposure to single-country sourcing. This shift has repercussions for contracting timelines and inventory strategies, triggering higher working capital needs during transitional periods. Logistics providers and specialty distributors have expanded value-added services, including bonded warehousing, deferred duty programs, and vendor-managed inventory solutions, to help clients mitigate cost volatility and maintain continuity of supply for patient care.

Clinicians and hospital procurement teams are adapting by strengthening specifications for raw material traceability and insisting on documented change control processes when substitutions occur. These measures preserve clinical confidence in compounded preparations and support continuity of therapy. Looking forward, tariff-driven realignments are likely to create opportunities for suppliers that can demonstrate robust quality systems, flexible manufacturing capacity, and reliable regional distribution networks.

In-depth segmentation intelligence revealing how formulation types, therapeutic uses, channels, end-users, and patch technologies define clinical adoption and operational priorities

Segmentation-level insights reveal distinct strategic imperatives across formulation types, therapeutic indications, distribution channels, end-user settings, and enabling technologies. Based on Formulation, market analysis covers Cream, Foam, Gel, Lotion, Ointment, and Spray, each offering differentiated application characteristics and stability profiles that influence prescribing behavior and patient adherence. Creams and lotions remain preferred where emollience is prioritized, while gels and foams are selected for cosmetically acceptable, fast-drying applications; sprays and ointments fill niche roles when occlusion or specific contact patterns are needed.

Based on Therapeutic Indication, the study considers Analgesic Pain Management, Anti-Inflammatory, Antibacterial, Antifungal, Dermatological Conditions, and Wound Healing, highlighting how clinical rationale informs formulation choice and dispenser instructions. In pain management and anti-inflammatory use cases, transdermal technologies can provide targeted exposure with reduced systemic burden. Antibacterial and antifungal preparations often require excipients that enhance penetration to the infection site while preserving microbial stability. Dermatological conditions and wound healing applications demand formulations that balance moisture control, barrier support, and active agent stability.

Based on Distribution Channel, analysis covers Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is further evaluated across Private Hospital Pharmacy and Public Hospital Pharmacy. The Online Pharmacy is examined across Aggregator Platform and Direct Website. The Retail Pharmacy is dissected into Chain Pharmacy and Independent Pharmacy. Each channel presents unique regulatory oversight, inventory management practices, and clinician engagement models. Hospital systems prioritize documented quality systems and traceability, online platforms emphasize digital ordering workflows and remote clinical support, and retail outlets leverage proximity and patient counseling as differentiators.

Based on End User, the assessment addresses Clinics, Dermatology Clinics, Homecare Settings, and Hospitals. The Clinics category is further split into General Clinics and Specialty Clinics, reflecting differences in prescriber expertise, patient volume, and therapeutic focus. Dermatology clinics frequently adopt specialized compounding regimens that require close clinical follow-up, while homecare settings demand packaging and instructions aligned with caregiver capabilities. Hospitals incorporate compounded topicals into inpatient formularies with controlled dispensing protocols and stewardship oversight.

Based on Technology, the report compares Conventional Formulations and Transdermal Patches. The Transdermal Patches are further classified as Matrix Patch and Reservoir Patch, each presenting trade-offs in release kinetics, manufacturing complexity, and regulatory scrutiny. Matrix patches typically offer simpler manufacturing and reduced leak risk, whereas reservoir patches can enable more precise rate control but require robust barrier systems and additional release-testing protocols. These technological distinctions influence supply chain requirements, quality control testing, and clinician education needs.

Regional dynamics and regulatory variance across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways and commercialization approaches

Regional dynamics shape access, regulatory expectations, and commercialization pathways for compounded topical therapeutics across major global markets. The Americas display a mature clinical adoption environment with sophisticated hospital pharmacy infrastructures and a high degree of clinician-driven customization. Regulatory bodies emphasize compounding quality standards and adverse event reporting, and private health systems often integrate specialty pharmacy services to support complex, personalized regimens.

Europe, Middle East & Africa presents a heterogeneous landscape where national regulatory frameworks differ markedly in their approach to compounding oversight and permitted scopes of practice. In some European jurisdictions, centralized pharmacopoeial standards and robust clinical networks support evidence-driven compounding practices, while other jurisdictions place greater emphasis on regional licensing and local quality controls. The Middle East and Africa regions are seeing increasing investment in capacity building and partnerships with established compounding laboratories to expand access to specialized topical preparations.

Asia-Pacific is characterized by rapid clinical innovation adoption, a growing number of specialty pharmacies, and expanding capabilities in both formulation science and localized manufacturing. Supply chain considerations, including import controls and raw material sourcing, vary across countries, influencing strategic decisions around regional production and distribution. In aggregate, these regional nuances affect how manufacturers prioritize registration pathways, clinical engagement strategies, and partnership models to ensure appropriate access and compliance.

Critical competitive attributes and partnership models that separate quality-driven compounding providers from transactional suppliers in topical therapeutic delivery

Competitive positioning in the compounded topical therapeutics space is anchored in three core pillars: demonstrable quality systems, clinically aligned service offerings, and scalable manufacturing or fulfillment capabilities. Leading compounding organizations invest in validated facilities, robust sterility and stability testing protocols, and transparent documentation that facilitates institutional contracting and clinician confidence. These investments mitigate risk and create differentiation in tender evaluations and formulary decisions.

Service differentiation extends beyond manufacturing to include clinical support, patient counseling, and partnership models with prescribers. Firms that offer evidence summaries, dosing guides, and therapeutic monitoring frameworks strengthen prescriber adoption and support adherence. On the operational side, companies that provide flexible fulfillment options-such as unit-dose packaging, home delivery, and integration with electronic prescribing systems-gain traction among retail and online distribution partners.

Strategic alliances are increasingly common, with specialty pharmacies forming preferred supplier relationships with hospital systems and contract manufacturers providing validated compounding lines for branded drug portfolios. Companies that can demonstrate rapid change control execution, reliable supply continuity, and an integrated approach to regulatory compliance are best positioned to win long-term institutional contracts and support diverse end-user needs.

Actionable strategic priorities for industry leaders to align supply resilience, clinical evidence generation, and omnichannel distribution to sustain competitive advantage

Industry leaders should prioritize a three-part action plan that aligns supply resilience, clinical evidence generation, and channel integration to secure sustainable advantage. First, strengthen supply chain architecture by diversifying raw material sources, investing in nearshoring where feasible, and implementing advanced vendor qualification frameworks that include documented change control and stability bridging studies. These steps reduce exposure to tariff and logistics volatility and support continuous patient access.

Second, commit resources to building clinical evidence and education programs that demonstrate the therapeutic rationale and real-world outcomes of compounded topicals. Collaborative studies with clinical centers, pragmatic registries, and prescriber training initiatives will accelerate appropriate adoption and support payer discussions. Translating clinical experience into clear prescribing guidance and monitoring protocols will also reduce variability in outcomes and reinforce clinician confidence.

Third, invest in channel and technology integration to meet clinicians and patients where they transact care. This includes interoperable e-prescribing interfaces, streamlined digital ordering workflows for aggregator platforms and direct websites, and fulfillment options tailored to hospitals, chain pharmacies, and independent retail outlets. By aligning operational excellence with clinical support and regulatory rigor, leaders can convert trust into enduring commercial relationships.

A rigorous, practitioner-focused research approach combining primary interviews, regulatory review, and technical literature to deliver operationally actionable insights

The research methodology underpinning this analysis combined structured primary research, regulatory review, and secondary literature synthesis to ensure a comprehensive, practice-oriented perspective. Primary inputs included in-depth interviews with hospital pharmacy directors, compounding pharmacists, formulary committee members, and clinical specialists to capture operational realities and clinical decision drivers. These conversations informed qualitative assessments of compounding processes, quality expectations, and adoption barriers.

Regulatory frameworks and guidance documents were reviewed to map compliance requirements and emerging oversight trends that affect compounding practice. The methodology also incorporated a detailed review of technical literature on formulation science, transdermal technologies, and excipient behavior to contextualize practical implications for stability, penetration, and patient acceptability. Supply chain analysis involved consultations with procurement leaders and distributors to understand sourcing constraints, logistics considerations, and tariff-related impacts.

Synthesis prioritized triangulation across sources to validate themes and identify actionable implications. Where variability in practice existed, the approach documented representative workflows and decision criteria rather than relying on single-source assertions. The goal of the methodology was to produce an evidence-based, operationally relevant set of insights that support strategy, procurement, and clinical engagement activities.

Synthesis of strategic imperatives and practical takeaways that reconcile clinical personalization, operational resilience, and regulatory expectations for compounded topicals

Compounded topical therapeutics represent a practical avenue for personalized, localized therapy that complements conventional pharmaceutical offerings. The sector is maturing as stakeholders adopt higher quality standards, invest in formulation innovation, and reconfigure supply chains to address geopolitical and tariff-driven disruptions. Clinicians continue to value the flexibility compounding offers for patient-specific dosing and formulation requirements, while procurement and regulatory stakeholders are shaping the practices needed to sustain safe, reliable access.

Strategically, organizations that can demonstrate validated quality systems, clinical support frameworks, and flexible distribution capabilities are best positioned to capture clinician trust and institutional contracts. Operational resilience-particularly in sourcing and logistics-will remain a differentiator as tariff dynamics and material availability continue to evolve. Meanwhile, transdermal technologies and improved excipient strategies present meaningful opportunities to expand clinical use cases and improve patient experience.

By integrating robust manufacturing controls, clinician-facing evidence, and channel-specific fulfillment solutions, stakeholders can align commercial objectives with patient safety and therapeutic effectiveness. The path forward favors collaborators who can bridge clinical rigor with operational execution and who can translate technical capability into tangible improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Compounded Topical Drug Market, by Formulation

  • 8.1. Cream
  • 8.2. Foam
  • 8.3. Gel
  • 8.4. Lotion
  • 8.5. Ointment
  • 8.6. Spray

9. Compounded Topical Drug Market, by Technology

  • 9.1. Conventional Formulations
  • 9.2. Transdermal Patches
    • 9.2.1. Matrix Patch
    • 9.2.2. Reservoir Patch

10. Compounded Topical Drug Market, by Therapeutic Indication

  • 10.1. Analgesic Pain Management
  • 10.2. Anti-Inflammatory
  • 10.3. Antibacterial
  • 10.4. Antifungal
  • 10.5. Dermatological Conditions
  • 10.6. Wound Healing

11. Compounded Topical Drug Market, by End User

  • 11.1. Clinics
    • 11.1.1. General Clinics
    • 11.1.2. Specialty Clinics
  • 11.2. Dermatology Clinics
  • 11.3. Homecare Settings
  • 11.4. Hospitals

12. Compounded Topical Drug Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Compounded Topical Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Compounded Topical Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Compounded Topical Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Compounded Topical Drug Market

17. China Compounded Topical Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3M Company
  • 18.6. Ascend Laboratories, Inc.
  • 18.7. Bausch Health Companies Inc.
  • 18.8. Fagron N.V.
  • 18.9. Fresenius Kabi AG
  • 18.10. Idelle Labs Ltd.
  • 18.11. ImprimisRx, LLC
  • 18.12. Merck & Co., Inc.
  • 18.13. PharMEDium Services, LLC
  • 18.14. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPOUNDED TOPICAL DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FOAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FOAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY LOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY LOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY LOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CONVENTIONAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANALGESIC PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANALGESIC PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANALGESIC PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTI-INFLAMMATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTI-INFLAMMATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIBACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIBACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIBACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIFUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ANTIFUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 194. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL COMPOUNDED TOPICAL DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY TRANSDERMAL PATCHES, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA COMPOUNDED TOPICAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)